ANDA 81266, held by Teva Parenteral Medicines. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 81266 (Methylprednisolone Sodium Succinate), held by Teva Parenteral Medicines, was first approved by FDA on Nov 30, 1992, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 1992 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone Sodium SuccinateEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Nov 12, 1993 | Supplement 1Labeling | Approved | None posted |
| Nov 30, 1992 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters